ArchiveApril 2017

AAN Siponimod Phase III positive in Secondary Progressive MS

Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis: Robert Fox , Ludwig Kappos , Amit Bar-Or , Bruce Cree , Gavin Giovannoni , Ralf Gold, Patrick Vermersch , Harold Pohlmann, Christian Wolf , Frank Dahlke , Erik Wallström , Tatiana Sidorenko Objective: To present safety and tolerability results of the randomized, double-blind, placebo-controlled, Phase...

Is progressive MS at long last getting the spotlight?

Drugs. 2017 Apr 20. doi: 10.1007/s40265-017-0726-0. [Epub ahead of print] Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. Nandoskar A, Raffel J, Scalfari AS, Friede T, Nicholas RS. Abstract It is well recognised that the majority of the impact of multiple sclerosis (MS), both personal and societal, arises in the progressive phase where disability...

More Media Nonsense…Not the Cause of Multiple Sclerosis, but maybe a pathway to damage

There is a story going round the media that the cause of multiple sclerosis has been found.  You can read the paper as it is open access and was published at the end of January. I have been accused of being HDAD with the post’s today…but ProfG has asked that we comment on this story ASAP. Is this the cause of MS? I would say absolutely not. It describes a way that nerves can...

AAN News: Low convertion to SPSS after alemtuzumab.

Dana Horakova, MD, PhD; Aaron Boster, MD; Tjalf Ziemssen, MD; Antonio Bertolotto, MD; Susan Goelz; Isabel Firmino, MD; Steven Cavalier, MD, FAAN; Karthinathan Thangavelu, PhD; Mark Freedman, MD, FAAN  Patients Who Received Alemtuzumab in CARE-MS I or II Show a Low Rate of Conversion From Relapsing-Remitting MS to Secondary Progressive MS Through 6 Years  Objective: To determine the rate...

Adenosine deaminase elevation in MS

Multiple sclerosis showing elevation of adenosine deaminase levels in the cerebrospinal fluid.Samuraki M, Sakai K, Odake Y, Yoshita M, Misaki K, Nakada M, Yamada M.Mult Scler Relat Disord. 2017 Apr;13:44-46. An 80-year-old man developed dysarthria, quadriplegia, sensory disturbance and ataxia in all limbs. Brain and spinal magnetic resonance imaging (MRI) revealed multiple enhanced lesions...

Detecting myelin

Myelin Detection Using Rapid Quantitative MR Imaging Correlated to Macroscopically Registered Luxol Fast Blue-Stained Brain Specimens.Warntjes JBM, Persson A, Berge J, Zech W.AJNR Am J Neuroradiol. 2017 . doi: 10.3174/ajnr.A5168. [Epub ahead of print] BACKGROUND AND PURPOSE: Myelin detection is of great value in monitoring diseases such as multiple sclerosis and dementia. However, most MR imaging...

Not in my Name again

Zakaria MMA, Mikhael SY, Hussein AKA, El-Din RAS, El-Malak HWA, Hewedi IH, Nadim HS.Failure of the vascular hypothesis of multiple sclerosis in a rat model of chronic cerebrospinal venous insufficiency. Folia Neuropathol. 2017;55(1):49-59 Chronic cerebrospinal venous insufficiency (CCSVI) is a series of stenotic malformations in the cerebrospinal venous outflow routes, which is postulated to...

Potassium Channels as a major autoimmune target in MS, it ain’t Kir 4.1

Zhong R1, Liang J, Tao A, Wu L, Yang X, Xu H, Huang Q, Zhuang S, Long Y, Gao C.Anti-KIR4.1 Antibodies in Chinese Patients with Central Nervous System Inflammatory Demyelinating Disorders. OBJECTIVES: The aim of this study was to explore the frequency of KIR4.1 antibodies in patients with multiple sclerosis (MS) and in control groups using a cell-based...

MS news maybe you will get access to fampridine

I was speaking to a pwMS and they told me that the company Acorda developing fampridine with Biogen has lost its patents in a court case, meaning that from 2018, generic fampridine may become available. At present it has not got the NICE seal of approval and is not considered cost effective and so in many place you get no access. Although there are surely a few more court battles to be had. The...

MS and EBV

If EBV is the driver of MS, then there must surely be evidence that something related to EBV that associates with disease activity. Does the Black Swan get it? Gieß RM, Pfuhl C, Behrens JR, Rasche L, Freitag E, Khalighy N, Otto C, Wuerfel J, Brandt AU, Hofmann J, Eberspächer B, Bellmann-Strobl J, Paul F, Ruprecht K. Epstein-Barr virus antibodies in serum and DNA load in saliva are not...

Translate

Categories

Recent Posts

Recent Comments

Archives